Background/Objectives: Transperineal MRI-fusion prostate biopsy under local anaesthesia is increasingly performed in the outpatient setting, which places greater weight on procedural tolerability. Psychological and anatomical determinants of pain have rarely been compared within a single model, and MRI-derived perineal anatomical parameters have not been evaluated. We aimed to identify factors associated with procedural pain and to determine at which step pain peaks. Methods: In this prospective, pre-registered, single-centre cohort study (OSF: osf.io/pbacu), 182 consecutive men referred for transperineal MRI–ultrasound fusion biopsy under local anaesthesia were assessed for eligibility, and 177 constituted the Full Analysis Set. State anxiety was measured with the STAI-S before and after biopsy. Pain was rated on a Numeric Rating Scale (NRS 0–10) by a nurse not involved in the procedure at four predefined steps: probe insertion, skin infiltration, periprostatic nerve block and core sampling. Midline perineal tissue thickness (MPT) and levator ani thickness were measured on pre-biopsy T2-weighted MRI by a radiologist blinded to outcomes. The primary outcome was the maximum NRS score; ten candidate predictors were entered simultaneously into a multivariable linear regression model. Results: Clinically significant pain (maximum NRS score ≥ 4) was reported by 157 of 177 men (88.7%). Pain differed markedly across steps (F(2.68, 472.39) = 230.51, p < 0.001, partial η² = 0.567) and peaked at the periprostatic nerve block (5.88 ± 2.03), exceeding core sampling by 2.62 points (95% CI 1.85–3.40). In multivariable analysis (R² = 0.192), pre-biopsy anxiety was the strongest independent predictor (standardised β = 0.30, partial R² = 0.094, p < 0.001), followed by prostate volume (β = 0.19, p = 0.014); MPT showed only an exploratory, borderline association (β = 0.17, p = 0.052). Core number, body mass index and levator ani thickness were not associated with pain. Conclusions: Most men undergoing transperineal MRI-fusion biopsy experience clinically significant pain, peaking at administration of the periprostatic block rather than at core sampling. Pre-procedural anxiety and prostate volume, both available beforehand, support simple risk stratification, while the block itself is the most logical target for analgesic improvement.

Background and Objectives: Recurrent urinary tract infection (rUTI) remains common and burdensome, with growing emphasis on antibiotic stewardship and non-antibiotic prevention. We characterized what women with rUTI know, do, and receive in everyday care and identified gaps between patient understanding and guideline-concordant management. Materials and Methods: We conducted a single-center, cross-sectional survey of consecutive adult women presenting with rUTI to a urology clinic in Poland. A structured questionnaire captured demographics, knowledge, symptoms and triggers, diagnostics, treatments and prevention, and satisfaction. Responses were standardized a priori; descriptive statistics and exploratory comparisons were performed (N = 36). Results: The mean age was 53.0 years (SD: 14.8). Only 36.1% identified the correct rUTI definition, while 83.3% recognized bacteria as the common cause. The symptom profile was dominated by frequency and dysuria (each 88.9%); 27.8% reported intercourse as a precipitant, and this was more frequent among sexually active women (43.5% vs. 7.7%; p = 0.031). Over half (55.6%) perceived no seasonality. The median number of episodes in the prior year was five (IQR 4–6). Urine culture was obtained before treatment in 38.9% and after treatment in 13.9%. The overall satisfaction with care was low to moderate (13.9% were very satisfied, 61.1% were moderately satisfied, and 25.0% were dissatisfied). Prior antibiotic exposure included ciprofloxacin (55.6%), furazidin (75.0%), and fosfomycin (47.2%). The uptake of preventive options was uneven: immunoactive vaccines accounted for 19.4%, methenamine hippurate for 16.7%, pelvic floor physiotherapy for 33.3%, and vaginal estrogen for 5.6% overall (9.5% among women ≥ 50 years). Conclusions: In this clinic-referred cohort, rUTI was frequent and disruptive, factual knowledge was limited, urine culture use was inconsistent, and fluoroquinolone exposure remained common. Preventive care was misaligned with guidelines, with underuse of vaginal estrogen and variable adoption of non-antibiotic strategies. Targeted education, stewardship, and structured access to evidence-based prevention may improve outcomes.